ALADDìV (The Latin American Alliance for the Development of in Vitro Diagnostics) is a non-profit entity, that aims the convergence and open dialogue among the different stakeholders in the health sector in relation to the following topics:

- Awareness of the need of an early, correct and with efficacy, with adequate specificity and sensitivity for the proposed objectives.
- Awareness of safety and efficacy aspects.
- Promotion of the access of patients to the new technologies in Health
- Motivation in the implementation of quality systems
- Advocacy for the regulatory convergence that will allow better predictability and cooperation among the American countries, especially in public health programs.

In 2021, ALADDìV presents its XI International Workshop and searches to foster the discussion among Academy, Regulatory Bodies, Ministries of Health, besides experts involved in health policy making, about the lessons learned in fighting COVID-19, emergency regulation of diagnostic tests and incorporation of new technologies for the facing different diseases like HIV, TB, Hanseniasis, HCV.

The Workshop has, as partners, the London School of Hygiene & Tropical Medicine, IDC – International Diagnostic Centre, Welcome Trust and Chattam House and will be held this year in Brasília, on Dec 6th and 7th, counting with participants from the whole continent.

**Background**

More than 1 billion people worldwide do not have access to adequate health care. In 2015, countries committed to a Sustainable Development Agenda with 17 Sustainable Development Goals (SDGs), calling for the United Nations and its partners to build a better world with no one left behind. The efforts to move towards Universal Health Coverage to achieve the SDGs will need to be underpinned by affordable and accessible quality-assured health products that include medicines, vaccines and diagnostic tests that can be used at the point of care (POC) at all levels of a health care system. For infectious diseases, POC diagnostic testing needs to be rapid
and timely enough for health care providers to begin treatment with an appropriate antimicrobial in order to ensure best possible patient management, and to slow the rising incidence of antimicrobial-resistant (AMR) infections. The COVID-19 pandemic has shown countries the important role that POC diagnostic tests play in outbreak control, resumption of activities and economic recovery.

The Chatham House, London School of Hygiene & Tropical Medicine (LSHTM), Innovate UK and the Wellcome Trust propose to work together with select countries and other stakeholders in different regions to explore options for accelerating market entry and adoption of quality-assured POC diagnostic tests. These regional consultations, in the case of Americas done together with ALADDIV, will contribute to a global event with UN agencies and major stakeholders on how to move forward.

Objectives of the consultation:

- To understand the need for accelerating access to diagnostics
- To share the key findings of the rapid assessment of regulatory and policy landscape
- To brainstorm on options for accelerating access to diagnostics
- To agree on options and next steps

Expected outcomes:

- Summary of options for accelerating diagnostic access in Africa
- Plan for moving forward as part of the Africa CDC’s Collaborative Initiative to Advance Diagnostics (AFCAD)

Enrollment: [https://us02web.zoom.us/webinar/register/WN_VTS0r6agR_W6luGSsNzl3Q](https://us02web.zoom.us/webinar/register/WN_VTS0r6agR_W6luGSsNzl3Q)

Apoio: